pyridoxine has been researched along with darunavir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bellistrì, GM; Cannizzo, ES; d'Arminio Monforte, A; Garau, M; Mancusi, D; Marchetti, G; Savoldi, A; Termini, R; Tincati, C | 1 |
1 review(s) available for pyridoxine and darunavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for pyridoxine and darunavir
| Article | Year |
|---|---|
T-cell phenotype and function following a first cART regimen containing either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor in HIV-infected late presenters: results from a retrospective, ex vivo study.
Topics: Adult; Anti-HIV Agents; Ascorbic Acid; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immunophenotyping; Male; Middle Aged; Niacin; Pyridoxine; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; T-Lymphocytes; Zinc Compounds | 2016 |